Skip to Content
Morningstar
Get 14 Days Free

Becton, Dickinson and Co BDX

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Veritor Demand Strong for Becton, Dickinson in the Second Quarter, Diabetes Spin-Off in 2022

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We're maintaining our fair value estimate and our narrow moat rating for Becton, Dickinson following the release of its second-quarter results. The second quarter saw similar underlying trends as the previous one; BD continues to benefit from COVID-19-related Veritor sales (albeit at lower levels) and is seeing some modest recovery in procedure volume in the developed world. BD also announced the spin-off of its diabetes franchise in 2022; we have not yet incorporated this in our model, but we don't anticipate the effect of this will be significant on our overall valuation of the company. Additionally, as we incorporate our new capital allocation framework, we are setting the company's rating at Standard.

Read Full Analysis

Company Profile

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Contact
1 Becton Drive
Franklin Lakes, NJ, 07417-1880
T +1 201 847-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Mar 31, 2021
Fiscal Year End Sep 30, 2021
Stock Type Slow Growth
Employees 72,000

Related

Market Update
The Winners of the New Definition of Infrastructure
Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Stock Strategist Industry Reports
A Coronavirus Vaccine, or Three, Could Be Available by Year-End
We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.
Karen Andersen
Stock Strategist Industry Reports
Slow Burn Likely Until Coronavirus Vaccines Are Widely Available
Resurgences in outbreaks make it clear that ending the pandemic will require more than diagnostic testing, contact tracing, and social distancing.
Karen Andersen
Premium Article
22 Meaningful Fair Value Hikes
These stocks enjoyed fair value increases in February. But are they worth buying today?
Susan Dziubinski
Our Picks
4 Dividend Stocks to Own
These stocks are among the top-10 holdings in several of our favorite dividend-growth funds.
Susan Dziubinski
US Videos
A Fast-Growing Slice of the Healthcare Sector for Your Radar
Life science and diagnostics firms offer attractive growth and moats, but be wary of valuations.
Michael Waterhouse
Fund Spy
A Thoughtful, Well-Researched Approach to Healthcare Investing
Silver-rated Fidelity Select Health Care's experienced manager takes a three-pronged approach to the sector.
Gregg Wolper
US Videos
M&A Activity Likely to Pick Up for Medical-Technology Firms
Becton Dickinson, Cardinal Health, and Abbott are all on track to make acquisitions.
Julie Utterback
Fund Times
Despite Manager Departure, This Fund Remains Appealing
Silver-rated Jensen Quality Growth is losing one of its skippers, but the fund has maintained its disciplined approach--and outperformance--through other departures.
Greg Carlson
Market Update
5 Investing Ideas From Top Dividend-Stock Fund Managers
Three fund managers share some dividend picks.
Manuela Badawy
Stock Analyst Update
Upgrading Our Growth Forecast for Becton, Dickinson
Across the firm, we are seeing the effects of significant R&D investments, with BD's pipeline the strongest it's been in our history of covering this narrow-moat medical technology company.
Alex Morozov
Fund Spy
Large-Growth Medalists at the Extremes of Sustainability
Quite a few good large-growth funds earn high Sustainability Ratings despite not being explicitly ESG-oriented.
David Kathman
Stock Strategist
Baxter's Headwinds Mostly Temporary
The company faces near-term challenges after the split, but we still like its moat.
Michael Waterhouse
Investing Specialists
Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers
Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.
The Morningstar Ultimate Stock-Pickers Team
Fund Spy
Nominees for 2014 Domestic-Stock Fund Manager of the Year
Five candidates who did more than ride the market's currents.
Dan Culloton
Credit Insights
Robust Liquidity Returns to Corporate Bond Market
New issue market reaches new volume records
David Sekera
Credit Insights
Unusual Activity in 10-Year Treasury Hits Markets
Only best-known issuers with strong balance sheets dared tap the new issue market.
David Sekera
Credit Insights
Heightened Volatility Results in Sloppy Corporate Bond Trading
While marriages are increasing in the health-care sector, conscious uncoupling increases in the technology sector.
David Sekera
US Videos
2 Names to Gain From Industry Trends
A retailer's attractive pricing and a health-care firm's favorable prospects create solid growth opportunities for Jensen manager Eric Schoenstein.
Greg Carlson
Stock Strategist Industry Reports
Patient Trends Improving, but Reimbursement Outlook Remains Bleak for Health Service Providers
Greater accountability creates a new level of operating uncertainty.
Michael Waterhouse

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.